LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Cumberland Pharmaceuticals Inc

Fermé

2.54 -4.51

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.49

Max

2.61

Chiffres clés

By Trading Economics

Revenu

3.2M

1.2M

Ventes

1.3M

12M

BPA

0.082

Marge bénéficiaire

10.656

Employés

91

EBITDA

1.2M

1.3M

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-15M

59M

Ouverture précédente

7.05

Clôture précédente

2.54

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Cumberland Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 juin 2025, 20:51 UTC

Résultats

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 juin 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 juin 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 juin 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 juin 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 juin 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 juin 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 juin 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 juin 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 juin 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 juin 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 juin 2025, 18:39 UTC

Market Talk
Résultats

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 juin 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 juin 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 juin 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 juin 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 juin 2025, 17:08 UTC

Résultats

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 juin 2025, 16:52 UTC

Acquisitions, Fusions, Rachats

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 juin 2025, 16:22 UTC

Résultats

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 juin 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27 juin 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 juin 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27 juin 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27 juin 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 juin 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparaison

Variation de prix

Cumberland Pharmaceuticals Inc prévision

Score Technique

By Trading Central

4.325 / 4.845Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.